Impact of the COVID-19 on the surgical management of bone and soft tissue sarcoma: A systematic review

Putro, Yuni Artha Prabowo; Magetsari, Rahadyan; Mahyudin, Ferdiansyah; Basuki, Muhammad Hardian; Saraswati, Paramita Ayu; Huwaidi, A. Faiz

doi:10.1016/j.jor.2023.02.013

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 Moreover, a surgical delay was observed in the Covid cohort with an increase of 41.5 days in the median time for surgery. The surgical delay was also observed in other studies, 29 although in general it was not recommended for operable patients without COVID-19 symptoms, in particular for grade 2–3 soft tissue sarcoma, bone sarcoma, gastrointestinal stromal tumour (GIST) and visceral sarcoma. 27 However, a decrease of 44 days in the median time for the neoadjuvant radiotherapy treatment was observed which was applied to new cases with localized disease and could be in concordance with recommendations of use to delay surgery or as hypofractionated radiotherapy.…”

Section: Discussionmentioning

confidence: 75%

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain

Carrillo-García,

Lacerenza,

Hindi

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background and objectives: Social distancing and quarantine implanted during the COVID-19 outbreak could have delayed the accession of oncologic patients to hospitals and treatments. This study analysed the management of sarcoma patients during this period in five Spanish hospitals. Design and methods: Clinical data from adult sarcoma patients, soft tissue and bone sarcomas, managed during the COVID-19 outbreak, from 15 March to 14 September 2020 (Covid cohort), were retrospectively collected and time for diagnosis, surgery and active treatments were compared with sarcoma patients managed during the same pre-pandemic period in 2018 (Control cohort). Results: A total of 126 and 182 new sarcoma patients were enrolled in the Covid and Control cohorts, respectively, who were mainly diagnosed as soft tissue sarcomas (81.0% and 80.8%) and at localized stage (80.2% and 79.1%). A diagnostic delay was observed in the Covid cohort with a median time for the diagnosis of 102.5 days (range 6–355) versus 83 days (range 5–328) in the Control cohort ( p = 0.034). Moreover, a delay in surgery was observed in cases with localized disease from the Covid cohort with a median time of 96.0 days (range 11–265) versus 54.5 days (range 2–331) in the Control cohort ( p = 0.034). However, a lower delay for neoadjuvant radiotherapy was observed in the Covid cohort with a median time from the diagnosis to the neoadjuvant radiotherapy of 47 days (range 27–105) versus 91 days (range 27–294) in the Control cohort ( p = 0.039). No significant differences for adjuvant radiotherapy, neoadjuvant/adjuvant chemotherapy and neoadjuvant/adjuvant palliative chemotherapy were observed between both cohorts. Neither progression-free survival (PFS) nor overall survival (OS) was significantly different. Conclusion: Delays in diagnosis and surgery were retrospectively observed in sarcoma patients during the COVID-19 outbreak in Spain, while the time for neoadjuvant radiotherapy was reduced. However, no impact on the PFS and OS was observed.

show abstract

Section: Discussionmentioning

confidence: 75%

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain

Carrillo-García,

Lacerenza,

Hindi

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…A recent systematic review has reported that post-surgical mortality in patients with bone sarcomas and STS during the pandemic has increased with an odds ratio of 1.14. Delays in surgeries were associated with a worse surgical outcome, which was aggravated in the case of a COVID-19 infection [39]. All these data highlighted the need for an alternate response to COVID-19, and telehealth played a significant role.…”

Section: Telemedicine and Surgerymentioning

confidence: 94%

Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities

Tsagkaris

Trygonis

Spyrou

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: The COVID-19 pandemic has created a challenging environment for sarcoma patients. Most oncology societies published guidelines or recommendations prioritizing sarcoma patients and established telehealth as an efficient method of approaching them. The aim of this review is the assessment of current evidence regarding the utilization of telemedicine in diagnosis, treatment modalities, telerehabilitation and satisfaction among sarcoma patients and healthcare providers (HP). Methods: This systematic review was carried out using the databases PubMed and Ovid MEDLINE according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: The application of telemedicine to the management of sarcoma has yielded improved clinical and psychological outcomes. Specifically, significant progress has been demonstrated in the areas of tele-oncology and telerehabilitation during the last decade, and the COVID-19 outbreak has accelerated this transition toward them. Telehealth has been proven efficient in a wide spectrum of applications from consultations on physical therapy and psychological support to virtual care symptom management. Both HP and patients reported satisfaction with telehealth services at levels comparable to in-person visits. Conclusions: Telehealth has already unveiled many opportunities in tailoring individualized care, and its role in the management of sarcoma patients has been established in the post-COVID-19 era, as well.

show abstract

Detrimental effect of COVID-19 pandemic on patients with extremity bone sarcoma. Reference center experience

Teterycz,

Szostakowski,

Rosińska

et al. 2024

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Impact of the COVID-19 on the surgical management of bone and soft tissue sarcoma: A systematic review

Cited by 3 publications

References 31 publications

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain

Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities

Detrimental effect of COVID-19 pandemic on patients with extremity bone sarcoma. Reference center experience

Contact Info

Product

Resources

About